<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: In 2009, several epidemiological studies suggested a higher frequency of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in insulin glargine -treated patients </plain></SENT>
<SENT sid="1" pm="."><plain>A number of follow-up epidemiological population studies as well as two randomized, controlled clinical studies, one a 5000-patient <z:hpo ids='HP_0000488'>retinopathy</z:hpo> study and the other a 12,000-patient cardiovascular outcomes trial (ORIGIN), found no higher frequency of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in glargine-treated patients </plain></SENT>
<SENT sid="2" pm="."><plain>AREAS COVERED: We reviewed the existing literature as well as U.S </plain></SENT>
<SENT sid="3" pm="."><plain>FDA records to investigate the association of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, <z:mp ids='MP_0002055'>diabetes</z:mp>, and insulin </plain></SENT>
<SENT sid="4" pm="."><plain>There is a 20 - 40% higher incidence of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients </plain></SENT>
<SENT sid="5" pm="."><plain>Certain <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> are more common, including hepatocellular and pancreatic <z:mp ids='MP_0002038'>carcinoma</z:mp>, <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, <z:e sem="disease" ids="C0740457" disease_type="Neoplastic Process" abbrv="">renal cancer</z:e>, and breast and <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e>, and non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>There are numerous inter-related factors which may promote both <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, including dietary patterns, <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:hpo ids='HP_0000855'>insulin resistance</z:hpo>, and <z:e sem="disease" ids="C0001973" disease_type="Mental or Behavioral Dysfunction" abbrv="">alcoholism</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Patients who receive insulin treatment are typically older and "sicker" than those who receive oral agents </plain></SENT>
<SENT sid="8" pm="."><plain>EXPERT OPINION: It is very difficult to prove causal associations between <z:mp ids='MP_0002055'>diabetes</z:mp> and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> due to the host of confounding factors </plain></SENT>
<SENT sid="9" pm="."><plain>The hypothesis that <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> and IGF-1 receptor activation promote <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> is strong, but confounded by the association of <z:hpo ids='HP_0000842'>hyperinsulinemia</z:hpo> with <z:hpo ids='HP_0001513'>obesity</z:hpo>, which separately promotes <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Although statistical techniques to adjust for confounding variables can improve epidemiological comparisons, the lesson of the glargine <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> controversy is that controlled clinical trials are the only means to definitely prove hypotheses </plain></SENT>
</text></document>